NR1H4 and metabolic dysfunction-associated steatohepatitis: However, several compounds now are undergoing Phase 3 clinical trials in patients with NASH, including farnesoid X receptor (FXR) agonist obeticholic acid (REGENERATE/NCT02548351), stearoyl-CoA desaturase 1 (SCD1) inhibitor aramchol (NCT04104321), C-C chemokine receptors type 2 (CCR2) and 5 (CCR5) dual antagonist cenicriviroc (AURORA/NCT03028740), glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (NCT04822181), and selective thyroid hormone receptor β (THRβ) agonist MGL-3196 (MAESTRO-NASH/NCT03900429).